Zobrazeno 1 - 10
of 147
pro vyhledávání: '"lantus"'
Autor:
Yazed AlRuthia, Ohud H. Bahari, Suliman Alghnam, Ali M. Alrumaih, Hassan Asiri, Mohammed Alshammari, Mansour Alhowimel, Hana A. Al-Abdulkarim
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
BackgroundThe advent of Basaglar®, which is a biosimilar insulin glargine formulation for Lantus® has brought hope that it will result in similar outcomes and lower costs. However, some health practitioners raised some concerns about the therapeuti
Externí odkaz:
https://doaj.org/article/acc1640056ac48d2a0c2b6f1aabca793
Autor:
Alexander Y. Mayorov, Roman V. Drai, Tatiana L. Karonova, Olga I. Avdeeva, Igor E. Makarenko, Ekaterina O. Koksharova, Ekaterina Е. Mishina, Yulia А. Sevastyanova, Olena V. Afonkina
Publikováno v:
Сахарный диабет, Vol 23, Iss 4, Pp 304-315 (2020)
Background: Prevention of the development of micro-and macrovascular complications in patients with diabetes melli-tus (DM) encouraged the search for insulin analogues that allow imitating, as close as possible, a normal physiological insulin secreti
Externí odkaz:
https://doaj.org/article/b3a6691ae08b4a68a1b2aa25127806f7
Autor:
Jiangjie Lu, Yong Zeng, Xiulin Yi, Hongmei Zhang, Lin Zhu, Lixin Jiang, Jing Li, Wei Zhou, Hong Zhu, Aijun Xiong
Publikováno v:
BMC Complementary Medicine and Therapies, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Recombinant insulin Lisargine is a new type of insulin. In this study, we aimed to compare its pharmacodynamic (PD) and pharmacokinetic (PK) with Lantus. Methods The PD test was performed by exploring the effect of single administ
Externí odkaz:
https://doaj.org/article/ad2a127d3e5f4f42877b6900e3f3f0ad
Autor:
Huiying Wang, Yunting Zhou, Xiaofang Zhai, Bo Ding, Ting Jing, Xiaofei Su, Huiqin Li, Jianhua Ma
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
AimThis study aims at evaluating glycemic control during Basalin or Lantus administration in adults with controlled type 2 diabetes mellitus using continuous glucose monitoring system (CGM).Methods47 patients with well-controlled T2DM using both Basa
Externí odkaz:
https://doaj.org/article/d01c178a87c6443f8a1209034651154c
Autor:
Dmytro Morozenko, Yevheniia Vashchyk, Andriy Zakhariev, Nataliia Seliukova, Dmytro Berezhnyi, Kateryna Gliebova
Publikováno v:
ScienceRise: Biological Science. :31-34
The aim:to analyze clinical cases of diabetes mellitus in cats and establish the effectiveness of clinical and laboratory research and treatment of animals with the help of insulin therapy. Materials and methods.The material for the study were domest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::353f1b3ba6765346df93726342dce54b
https://doi.org/10.15587/2519-8025.2022.266536
https://doi.org/10.15587/2519-8025.2022.266536
Autor:
V.V. Poltorak
Publikováno v:
Mìžnarodnij Endokrinologìčnij Žurnal, Vol 12, Iss 4.76, Pp 59-72 (2016)
This review examines the new formulation of insulin glargine (recombinant) in the form of injections 300 U/ml (Gla‑300, Toujeo®). Gla‑300 is a next generation basal insulin with a novel formulation of insulin glargin delivering the same amount o
Externí odkaz:
https://doaj.org/article/40532c6d3973434e8b9d190333c5b588
Publikováno v:
ScienceRise: Biological Science; No. 4(33) (2022); 31-34
ScienceRise: Biological Science; № 4(33) (2022); 31-34
ScienceRise: Biological Science; № 4(33) (2022); 31-34
The aim: to analyze clinical cases of diabetes mellitus in cats and establish the effectiveness of clinical and laboratory research and treatment of animals with the help of insulin therapy. Materials and methods. The material for the study were dome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=scientific_p::1c627633b899476580ebafd52b0b324e
http://journals.uran.ua/sr_bio/article/view/266536
http://journals.uran.ua/sr_bio/article/view/266536
Autor:
V.V. Poltorak
Publikováno v:
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY; № 4.76 (2016); 59-72
Международный эндокринологический журнал-Mìžnarodnij endokrinologìčnij žurnal; № 4.76 (2016); 59-72
Міжнародний ендокринологічний журнал-Mìžnarodnij endokrinologìčnij žurnal; № 4.76 (2016); 59-72
Международный эндокринологический журнал-Mìžnarodnij endokrinologìčnij žurnal; № 4.76 (2016); 59-72
Міжнародний ендокринологічний журнал-Mìžnarodnij endokrinologìčnij žurnal; № 4.76 (2016); 59-72
This review examines the new formulation of insulin glargine (recombinant) in the form of injections 300 U/ml (Gla‑300, Toujeo®). Gla‑300 is a next generation basal insulin with a novel formulation of insulin glargin delivering the same amount o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::460fed57c1929fa3b114d0e5d645948c
https://doi.org/10.22141/2224-0721.4.76.2016.77809
https://doi.org/10.22141/2224-0721.4.76.2016.77809
Publikováno v:
Mìžnarodnij Endokrinologìčnij Žurnal, Vol 11, Iss 7.71, Pp 22-35 (2015)
This review, consisting of two parts, considers a new formulation of insulin glargine (rDNA origin) in the form of injections 300 U/ml (Gla-300, Toujeo®). Gla-300 is a next generation basal insulin with a novel formulation of insulin glargin deliver
Externí odkaz:
https://doaj.org/article/46fa0988c29a4df0a0ac69162f35a849
Publikováno v:
Терапевтический архив, Vol 87, Iss 10, Pp 42-49 (2015)
Aim. To implement in 2009—2012 the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen in patients with type 1 diabetes mellitus (DM) to evaluate the efficienc
Externí odkaz:
https://doaj.org/article/ef7d9c95ddd243039e3f28f5fe344458